Key facts
- Accuryn’s last known valuation is $111.0M (Sep 2025).
- It has raised $113.2M; the latest was Seed Round ($5.5M) in Sep 2025.
- Notable investors include Ceros..
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Accuryn
- ·The full record, as it builds
Funding rounds
No funding rounds for Accuryn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accuryn
Developer of predictive health monitoring system designed to improve patient care using artificial intelligence and machine insights. The company's platform provides real-time measurement of intra-abdominal pressure, urine output, and core body temperature in degrees Fahrenheit and degrees Celcius, enabling medical teams to predict adverse outcomes in critical care settings better.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2011
- Employees
- 37
- Website
- accuryn.com/
- Ownership
- Privately Held (backing)
Accuryn doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accuryn shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accuryn in its N-PORT filings yet. We sweep new filings monthly.